EMA Authorised: Teriflunomide Viatris (previously Teriflunomide Mylan) (teriflunomide) — Viatris Limited

View source ↗

Summary

The EMA authorised Teriflunomide Viatris for treatment of relapsing-relapsing multiple sclerosis, with Viatris Limited as the marketing authorisation holder (pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Teriflunomide Viatris (teriflunomide)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting. MAH: Viatris Limited. Decision date: 11/12/2025